Skip to main content
OpenTrials
Completed

NCT Number: NCT03380052

OLGA and OLGIM Stage System for Gastric Cancer

To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Stomach Neoplasms Atrophic Gastritis Digestive System Diseases Digestive System Neoplasms Gastritis Gastritis, Atrophic Gastroenteritis Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Metaplasia Neoplasms Neoplasms by Site Stomach Diseases

Age range

25 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 463-707, South Korea

About this study

To validated the OLGA and OLGIM staging system with serum pepsinogen to estimate gastric cancer risk according to Lauren's histologic classification in South Korea, where the incidence rate of GC is high. In addition, the investigators attempted to investigate the interaction among the several risk factors including OLGA or OLGIM staging system for the risk of GC to help establish surveillance strategy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Control group
  • those who were between 25 and 80 years old and did not have any evidence of gastric cancer and gastric dysplasia, esophageal tumor and MALToma in upper gastrointestinal endoscopy
  • Gastric cancer group
  • Patients diagnosed as gastric cancer in the upper gastrointestinal endoscopy at the time of participating in the study between 25 and 80 years old.

Exclusion criteria

  • history of previous gastrointestinal surgery,
  • any other malignancy
  • cardia cancer
  • who do not perform endoscopic biopsy
  • pathologically proven gastric dysplasia

Treatment and study plan

Primary outcomes

  1. The evaluation of OLGA and OLGIM stage systems with serum pepsinogen for prediction of gastric cancer risk

    Time frame: per 1 year

    To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification

Sponsors and collaborators

Lead sponsor

Seoul National University Bundang Hospital

Other

Collaborators

  • National Clinical Research Coordination Center, Seoul, Korea

Registry information

Official study title

The Evaluation of OLGA and OLGIM Stage Systems for Prediction of Gastric Cancer Risk and Interaction With Other Risk Factors According to Lauren's Classification

Important dates

Study start
2006
Primary completion
2021
Study completion
2022
First posted
Dec 20, 2017
Registry last updated
Apr 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.